• Cytokinetics has already launched MYQORZO (aficamten) in Germany for adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy, following earlier approvals in the U.S., China and the EU based on positive Phase 3 SEQUOIA-HCM data published in the New England Journal of Medicine.
• The German launch marks MYQORZO’s first commercial entry into Europe, expanding its treated patient population and reinforcing its clinically validated profile across multiple major markets.
• Now we’ll examine how MYQORZO’s first European commercial launch, backed by SEQUOIA-HCM outcomes data, affects Cytokinetics’ broader investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Cytokinetics Investment Narrative Recap

To own Cytokinetics, you need to believe aficamten can become a meaningful commercial franchise in hypertrophic cardiomyopathy while the company manages high ongoing losses and funding needs. The first European launch of MYQORZO in Germany modestly de-risks the near term focus on execution and reimbursement, but does not remove the core risk around scaling sales fast enough to support Cytokinetics’ growing expense base and recently expanded share count.

The recent US$650.0 million follow on equity raise in May 2026 is especially relevant here, as it highlights both the capital intensity of Cytokinetics’ launch plans and the company’s willingness to issue new shares while still loss making. Against that backdrop, MYQORZO’s German launch adds an early proof point that the new capital is being deployed into actual market access, a key piece of the near term investment story.

Yet despite the progress in Germany, investors should also be aware that...

Cytokinetics' narrative projects $808.9 million revenue and $103.3 million earnings by 2029. This requires 109.4% yearly revenue growth and an earnings increase of about $888 million from -$785.0 million today.

Uncover how Cytokinetics' forecasts yield a $92.94 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Before this launch, the most optimistic analysts were assuming revenue could reach about US$1.3 billion by 2029, but if you are weighing that against the risk of slower reimbursement and uptake in new markets, it shows how far views can differ and why this latest news may reshape how you think about Cytokinetics’ potential path from here.

Explore 4 other fair value estimates on Cytokinetics - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cytokinetics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Cytokinetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cytokinetics' overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.